Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1

Archives of Gynecology and Obstetrics

Volumn 289, Issue 1, 2014, Pages 141-147

  Engel, Jörg B ^a   Honig, Arnd ^b   Kapp, Michaela ^b   Hahne, Jens C ^b   Meyer, Susanne R ^b   Dietl, Johannes ^b   Segerer, Sabine E ^b  

^a CARITAS KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

AKT; Treg infiltration; Triple negative breast cancer; Tumor immune escape

Indexed keywords

ESTROGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR FOXP3; BRCA1 PROTEIN; CD274 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL INFILTRATION; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MCF 7 CELL LINE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION;

ANTIGENS, CD274; BRCA1 PROTEIN; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; T-LYMPHOCYTES, REGULATORY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR ESCAPE;

EID: 84891845828     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2922-9     Document Type: Article

References (43)

1. Jemal A et al (2010) Cancer statistics. CA Cancer J Clin 60(5):277-300
2. Prat A, Perou CM (2010) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5-23
3. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26(1):1-10
4. Alizadeh AA et al (2001) Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195(1):41-52 (Pubitemid 32899044)
5. Barrett SV (2010) Breast cancer. J R Coll Physicians Edinb 40(4):335-338 quiz 339
6. Schneider BP et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010-8018
7. Hennessy BT et al (2007) Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421-7431
8. Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429-4434 (Pubitemid 47219710)
9. Tanner B et al (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24(26):4317-4323 (Pubitemid 46630790)
10. Rakha EA et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32 (Pubitemid 46120191)
11. Haffty BG et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652-5657 (Pubitemid 46631305)
12. Nahleh Z (2010) Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook. Med Oncol 27(2):531-539
13. Olkhanud PB et al (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69(14):5996-6004
14. Tischkowitz M et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134 (Pubitemid 47272190)
15. Paradiso A, Formenti S (2011) Hereditary breast cancer: clinical features and risk reduction strategies. Ann Oncol 22(Suppl 1):i31-i36
16. Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7(12):702-707
17. Alfonso-De Matte MY et al (2002) Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 62(16):4575-4578
18. Darnell RB, Posner JB (2003) Observing the invisible: successful tumor immunity in humans. Nat Immunol 4(3):201 (Pubitemid 36322123)
19. Wolf AM et al (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606-612 (Pubitemid 36182591)
20. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2(5):373-382 (Pubitemid 37328950)
21. Algarra I, Cabrera T, Garrido F (2000) The HLA crossroad in tumor immunology. Hum Immunol 61(1):65-73 (Pubitemid 30058768)
22. Marincola FM et al (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
23. Seliger B et al (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12(1):3-13 (Pubitemid 34087893)
24. Kim R et al (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66(11):5527-5536 (Pubitemid 43927099)
25. Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369-380 (Pubitemid 41579832)
26. Kryczek I et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871-881
27. Kryczek I et al (2006) Cutting Edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T Cells. J Immunol 177(1):40-44 (Pubitemid 43939113)
28. Curiel TJ et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942-949 (Pubitemid 39273735)
29. Ling X et al (2010) Mesenchymal Stem Cells Overexpressing IFN-beta Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron 3(1):83-95
30. Tan W et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548-553
31. Black MM, Speer FD (1956) In vitro and clinical effects of urethane plus triethylene melamine on human breast cancer. Surg Gynecol Obstet 102(4):420-426
32. Ladoire S et al (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65-72
33. Black MM, Opler SR, Speer FD (1956) Structural representations of tumor-host relationships in gastric carcinoma. Surg Gynecol Obstet 102(5):599-603
34. Mahmoud SM et al (2011) An evaluation of the clinical significance of FOXP3 + infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99-108
35. Denkert C et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105-113
36. Ladoire S et al (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125(1):65-72
37. Yi T et al (2011) Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J Immunol 186(5):2739-2749
38. Wang S, Chen L (2011) Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol 344:245-267
39. Parsa AT et al (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13(1):84-88 (Pubitemid 46067390)
40. Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515-1527
41. Lopez-Knowles E et al (2010) PI3 K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126(5):1121-1131
42. Lehmann BD et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767
43. Righi E et al (2011) CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71(16):5522-5534